Kuros Biosciences (XSWX:KURN) Interest Expense : CHF-0.19 Mil (TTM As of Dec. 2023)

View and export this data going back to 2002. Start your Free Trial

What is Kuros Biosciences Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Kuros Biosciences's interest expense for the six months ended in Dec. 2023 was CHF 0.86 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-0.19 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Kuros Biosciences's Operating Income for the six months ended in Dec. 2023 was CHF -8.66 Mil. Kuros Biosciences's Interest Expense for the six months ended in Dec. 2023 was CHF 0.86 Mil. Kuros Biosciences did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kuros Biosciences Interest Expense Historical Data

The historical data trend for Kuros Biosciences's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kuros Biosciences Interest Expense Chart

Kuros Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.65

-0.85

-1.38

-0.15

-0.19

Kuros Biosciences Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Interest Expense	Get a 7-Day Free Trial															-1.25	-3.35	3.21	-1.04	0.86

Kuros Biosciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF-0.19 Mil.

Kuros Biosciences (XSWX:KURN) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kuros Biosciences's Interest Expense for the six months ended in Dec. 2023 was CHF0.86 Mil. Its Operating Income for the six months ended in Dec. 2023 was CHF-8.66 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2023 was CHF1.57 Mil.

Kuros Biosciences's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

The higher the ratio, the stronger the company's financial strength is.

Kuros Biosciences (XSWX:KURN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Kuros Biosciences Ltd (XSWX:KURN) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

CSBTF:USA KURNz:UK

Address

Wagistrasse 25, Schlieren, Zurich, CHE, 8952

Website

https://www.kurosbio.com

Kuros Biosciences Ltd is a Swiss-based biopharmaceutical company focused on the development of innovative products for tissue repair and bone regeneration. It operates through the following segments: Medical devices, Pharmaceuticals and Legacy portfolio. The Medical devices segment includes products such as MagnetOs and Attrax. The Pharmaceuticals segment includes products such as Fibrin-PTH, a drug-biologic combination that promotes targeted and controlled bone formation through the induction of osteoprogenitor cell differentiation, enhancement, of osteoblast proliferation and increasing the lifespan of bone-forming cells. The Legacy portfolio segment includes all other products that do not belong to the group's core business strategy.

Kuros Biosciences (XSWX:KURN) Headlines

No Headlines